Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer

Alfred I. Neugut, Grace Clarke Hillyer, Lawrence H. Kushi, Lois Lamerato, Nicole Leoce, Christine B. Ambrosone, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Dawn L. Hershman

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

One year of trastuzumab therapy is recommended for women with HER2-positive breast cancer ≥1.0 cm in size to increase survival and is considered for women with tumors 0.5–0.9 cm in size. We analyzed compliance with trastuzumab among women with HER2-positive breast cancer in a prospective cohort study. Of 1145 recruited patients with breast cancer, 152 were HER2-positive (13.2 %), of whom 126 had tumors ≥1.0 cm; 110/126 (87.3 %) of these initiated trastuzumab. Non-receipt was associated with older age, better prognosis tumors, and with non-receipt of adjuvant chemotherapy. Of the 110 who initiated treatment, 18 (15 %) did not complete treatment, 15 (83 %) of them because of cardiotoxicity. Of 20 women with tumors 0.5–0.9 cm, 5 (25 %) initiated trastuzumab. Compliance with trastuzumab was very high among those with HER2-positive breast cancer, as was the completion of the recommended therapy.

Original languageEnglish (US)
Pages (from-to)780-785
Number of pages6
JournalBreast Cancer
Volume21
Issue number6
DOIs
StatePublished - 2014
Externally publishedYes

Keywords

  • Adherence
  • Adjuvant therapy
  • Breast cancer
  • Early discontinuation
  • Non-initiation
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Neugut, A. I., Hillyer, G. C., Kushi, L. H., Lamerato, L., Leoce, N., Ambrosone, C. B., Bovbjerg, D. H., Mandelblatt, J. S., & Hershman, D. L. (2014). Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer, 21(6), 780-785. https://doi.org/10.1007/s12282-014-0543-1